Back to Headlines
Business
Jun 09, 2026
Analyzed by GPT OSS 120B

GSK to Acquire US Cancer Specialist Nuvalent for $10.6bn

AI Summary
British drugmaker GSK announced a $10.6bn purchase of Boston‑based Nuvalent, adding two late‑stage lung‑cancer drugs to its pipeline. The deal, the largest in GSK’s history, is expected to boost oncology revenues and support a £40bn sales target by 2031.

British drugmaker GSK announced the acquisition of Boston‑based cancer specialist Nuvalent for $10.6bn (£7.9bn), securing two late‑stage non‑small cell lung‑cancer therapies and marking the biggest deal in the company’s history.

Deal Structure and Late‑Stage Assets

The transaction brings Nuvalent’s two next‑generation drugs—zidesamtinib and neladalkib—into GSK’s portfolio. Both are under FDA review, with decisions slated for September and November, and are slated for launch later this year if approved.

Financial Scale and Revenue Projections

  • $10.6bn purchase price (≈ £7.9bn)
  • Each drug is projected to become a multi‑billion‑dollar blockbuster, potentially generating several billion dollars in annual sales.
  • GSK expects the new assets to start contributing to profit from 2027.

Strategic Impact on GSK’s Oncology Ambitions

Under new CEO Luke Miels, GSK is accelerating its oncology push that began under former chief Emma Walmsley. The acquisition adds a ready‑made lung‑cancer platform and complements the recently bought food‑allergy biotech RAPT, aligning with GSK’s target of >£40bn in annual sales by 2031.

Outlook: Market Position and Pipeline Growth

Assuming FDA approval, the two drugs could fill a tolerability gap for non‑smoking adults aged 40‑50, predominantly female, and strengthen GSK’s competitive stance against rivals. The deal also provides a launchpad for the late‑stage candidate Ris‑Rez, which could broaden GSK’s cancer portfolio beyond lung indications.